Evidence map›Paper›PMID 41255528›Full record

ArticleFrontiers in endocrinology2025

Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.

Deyong Yue, Xuesheng Hua, Ling Zhu, Jun Wang, Lihua Gu, Zhengxia Yuan, Wenle Jian, Yirong Chen, Guoliang Meng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Deyong Yue *Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Chongming, Shanghai, China.
Xuesheng Hua *Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Chongming, Shanghai, China.
Ling Zhu *Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Chongming, Shanghai, China.
Jun Wang *Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Chongming, Shanghai, China.
Lihua GuChongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Chongming, Shanghai, China.
Zhengxia YuanNantong University Xinglin College, Nantong, Jiangsu, China.
Wenle JianNantong University Xinglin College, Nantong, Jiangsu, China.
Yirong ChenGeneral Surgery Department of Wuxi No.8 People's Hospital, Wuxi, Jiangsu, China.
Guoliang MengDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to identify the risk factors associated with gastrointestinal adverse events induced by semaglutide in patients with type 2 diabetes mellitus (T2DM) and to develop a predictive risk model. Methods: A total of 215 patients with T2DM admitted to our hospital between June 2022 and December 2024 were enrolled. Participants were divided into two groups based on the presence ( Results: In a cohort of 215 patients with T2DM, 41 individuals (19.07%) experienced gastrointestinal adverse events attributed to semaglutide administration. Logistic regression analysis identified concomitant gastrointestinal disorders [95% confidence interval (CI): 2.074-9.808, Conclusion: Patients with T2DM exhibit a significant incidence of gastrointestinal adverse events associated with semaglutide use. The presence of gastrointestinal comorbidities, alcohol consumption, and α-glucosidase inhibitor therapy are independent risk factors. The developed nomogram effectively predicts the likelihood of semaglutide-related gastrointestinal adverse events in this patient population.

Indexed as

Diabetes Mellitus, Type 2Gastrointestinal DiseasesGlucagon-Like PeptidesHypoglycemic AgentsAdultAgedFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedNomogramsRisk AssessmentRisk FactorsSemaglutideGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsSemaglutidealcoholgastrointestinal adverse eventsrisk prediction modelsemaglutidetype 2 diabetes mellitusα-glucosidase inhibitors

Identifiers

PMID41255528
PMCPMC12620217

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.